Skip to main content
Alexey Danilov, MD, Oncology, Duarte, CA

AlexeyDanilovMD

Oncology Duarte, CA

Hematologic Oncology

Professor at City of Hope National Medical Center

Dr. Danilov is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Danilov's full profile

Already have an account?

  • Office

    Division of Lymphoma
    1500 East Duarte Road
    Duarte, CA 91010
    Phone+1 626-256-4673
    Fax+1 626-389-3058

Summary

  • Dr. Danilov earned his medical degree in Russia and completed a fellowship in hematology/oncology at Tufts Medical Center, in Boston, United States. He is a physician-scientist with background in molecular biology and cancer cell signaling and expertise in oncologic drug development. He leads an independent research program in B-cell malignancies which bridges the understanding of B-cell biology with early clinical evaluation of novel therapeutics.
    As a Director of Early Phase Therapeutics Program and a leader of the Lymphoma Center, Dr. Danilov guides an effort in experimental therapeutics at the City of Hope National Medical Center. His group’s pre-clinical focus is on evaluation of novel targets in the ubiquitin-proteasome system and oncogenic role of cyclin-dependent kinase-9. In addition, his group performs correlative science on multiple clinical trials. He received peer-reviewed funding from the National Cancer Institute (R01), Leukemia and Lymphoma Society, American Society of Hematology and Lymphoma Research Foundation, and serves as Co-Chair for Translational Medicine of the Southwest Oncology Group Lymphoma Committee.
    Clinically, Dr. Danilov is a practicing medical oncologist specializing in the care of patients with CLL and lymphoma. Building on his pre-clinical discoveries, he launched multiple early-phase clinical trials with novel agents. As a member of industry and SWOG committees and a leader within the Early Therapeutics Clinical Trials Network, he participates in drug development on a global scale.

Education & Training

  • Tufts Medical Center
    Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Brown University
    Brown UniversityResidency, Internal Medicine, 2004 - 2007
  • Yaroslavl Med Acad
    Yaroslavl Med AcadClass of 1997

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2019 - 2025
  • OR State Medical License
    OR State Medical License 2014 - 2023
  • NH State Medical License
    NH State Medical License 2010 - 2015
  • RI State Medical License
    RI State Medical License 2005 - 2007
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Leukemia and Lymphoma Society Scholar LLS, 2018

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
    Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline SettingDecember 9th, 2024
  • Promising Results with Epcoritamab Monotherapy in Relapsed/Refractory CLL
    Promising Results with Epcoritamab Monotherapy in Relapsed/Refractory CLLDecember 8th, 2024
  • Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
    Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary AnalysisDecember 8th, 2024
  • Join now to see all